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Mathematical models are a useful tool for investigating a
large number of questions in metabolism, genetics, and
gene–environment interactions. A model based on the
underlying biology and biochemistry is a platform for in
silico biological experimentation that can reveal the
causal chain of events that connect variation in one
quantity to variation in another. We discuss how we
construct such models, how we have used them to
investigate homeostatic mechanisms, gene–environment
interactions, and genotype–phenotype mapping, and
how they can be used in precision and personalized
medicine.model are sufficient to explain the observed, or desired,
results. This is one of the main points made by JeremyWe began more than a dozen years ago creating math-
ematical models in order to understand the systems
behavior of a variety of metabolic networks that are im-
portant for human health. In doing so, we were amazed
at the plethora of regulatory and control mechanisms
that have evolved to keep these systems functional in the
face of genetic mutations and large changes in environ-
mental inputs. The study of these regulatory mecha-
nisms has led us, in turn, to devise methods to study
four interlocking complex ideas: homeostatic plateaus,
cryptic genetic variation, predisposition to disease, and
precision or personalized medicine. The article is not
intended as a review of the field, but as a description of
our approach, the methods we have created, and our
journey towards a practical understanding of these fun-
damental biological ideas.
A model gives voice to our assumptions about how
something works. Every biological experiment is designed
within the context of a conceptual model and its results
cause us to confirm, reject, or alter that model. Conceptual
models are always incomplete because biological systems* Correspondence: hfn@duke.edu
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(http://creativecommons.org/publicdomain/zeare very complex and incompletely understood. Moreover,
and as a purely practical matter, experiments tend to be
guided by small conceptual models of only a very small part
of a system, with the assumption (or hope) that the
remaining details and context do not matter or can be
adequately controlled.
Mathematical models are formal statements of con-
ceptual models. Like conceptual models, they are typic-
ally incomplete and tend to simplify some details of the
system. But what they do have, which experimental
systems do not, is that they are completely explicit about
what is in the model, and what is not. Having a com-
pletely defined system has the virtue of allowing one to
test whether the assumptions and structure of the
Gunawardena in his essay that initiated this series of
expository articles [1].Modeling is like experimentation
Mathematical models should not be ends in themselves.
If they are to be of use, they should illuminate interest-
ing things about the biology of a system or allow the
user, by in silico experimentation, to discover things that
would be difficult (e.g., severely reduce nutrient input),
unethical (e.g., knock out or modify a gene in humans)
or expensive (e.g., change the expression levels of differ-
ent combinations of genes), or impractical to do in vivo
or in vitro.
Ideally, a well-validated mathematical model is a tool,
just like a microscope. It is a tool that complements
other tools used in biological investigations, and it oper-
ates best (or at least most usefully) when there is an
active interaction between modelers and experimenters.
Experiments provide parameter values, functions and
interactions that are essential for constructing the top-
ology and kinetics of a model. A model, in turn, can
suggest new experiments or help explain unexpected
results. New experimental results improve a model
and a model can guide the next round of experiments.is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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one to advance understanding more quickly and more
accurately than would be possible with experimenta-
tion alone.Complex metabolic networks
We have focused most of our modeling studies on meta-
bolic networks that are relevant to human health [2–13].
These systems are inherently interesting, and there are
always large amounts of data and observations that need
to be understood and explained. Sometimes data are
contradictory or inconsistent, and that can lead to contro-
versies; mathematical modeling can help provide explana-
tions for the observed differences. More importantly,
because these systems have been studied for a very long
time there are a lot of structural and quantitative data that
can be used to determine functional relationships and
parameters. Metabolic systems are very complex and typ-
ically have many regulatory mechanisms (see below), so
knowledge of the kinetics of individual reactions, though
important, does not by itself explain the behavior of the
whole system. In such a situation, mathematical models
are essential to gain understanding at the systems level.
Since the purpose of our modeling is not to produce a
model but to produce an exploratory and explanatory
tool, we focus on systems where the kinetics of individ-
ual reactions or transporters have been well-studied ex-
perimentally. The aim of our work is to develop models
that can help explain puzzling, conflicting, or contradict-
ory experimental or clinical findings, and that can also
be used to deduce the causal chain between genetic vari-
ation and phenotypic variation.Differential equation models and reaction kinetics
We normally work on metabolic systems in which the
number of molecules of the species of interest is large
enough that we can model the system by ordinary differ-
ential equations (ODEs) for the concentrations of the
species (the well-mixed assumption). These differential
equations simply reflect mass balance. The rate of change
of a metabolite is the sum of the rates of the reactions by
which it is made minus the rates of the reactions in which
it is used. These rates are complicated, usually highly non-
linear, formulas that express the rates as functions of the
current values of one or more metabolite or allosteric
regulator concentrations. These functions, the reaction
kinetics, and the associated parameter values are obtained
from the literature and from a large network of collabora-
tors who perform experimental or clinical studies. The
time courses of solution curves for different choices of
inputs or parameter values are obtained by solving the
ODEs in MatLab (Mathworks, Natick, MA, USA). If a
system is large, we start by making mathematical modelsof small subsystems. Only when the subsystems are well
understood do we study the whole system.
Model testing
Models are inevitably limited, and can in fact be biased,
by the data used to derive the equations and parameter
values. This is especially problematic when a model is
based on a small amount of data. It is essential, there-
fore, to continually test a model against new data that
did not go into its construction. If the model cannot
reproduce the basic trends in the data, then one knows
that some new biological or biochemical ideas need to
be added. On the other hand, if the model performs well
with the new data, one’s confidence is increased that the
model represents physiological reality. In this sense, the
‘model’ is not a fixed object, but continually evolves
through testing it against data and revising it accordingly.
Of necessity one has to make a choice about the par-
ameter values in a deterministic mathematical model.
They are initially selected from the literature, although
those values often vary considerably from publication to
publication. The values are then gradually refined by test-
ing the model against a broad diversity of data from
experimental perturbations, dose–response studies, effects
of mutations, and clinical studies. A good model should
eventually reproduce, with some accuracy, a broad diver-
sity of experimental data without having to fiddle with the
parameter values. The result is a kind of ‘average’ or
‘normal’ model. Of course it cannot be expected to give an
accurate representation of individual variability. To do
that, we create population models based on our determin-
istic models (see below).
The importance of homeostatic mechanisms
Metabolic systems are subject to hourly, daily, and sea-
sonal variation in input and demand. Moreover, individ-
uals and populations have different genetic makeups
that can affect the expression and activity of enzymes
and transporters in metabolic networks. Yet there are
critical reactions and metabolite levels that must be
maintained in the face of this environmental and genetic
variation, or that must be adjusted to meet temporary
increases in demand without compromising other im-
portant reactions in the system.
All the metabolic systems that we have studied contain
homeostatic mechanisms that accomplish this task. These
mechanisms include product inhibition (as one might
expect), but also substrate inhibition and allosteric regula-
tion, both positive and negative, of enzymes by metabo-
lites in distant parts of the network. We will illustrate
these mechanisms through several specific examples.
Substrate inhibition is an interesting phenomenon:
as the concentration of substrate increases the rate of
the reaction decreases because the substrate binds at
Fig. 2. Homeostasis of extracellular dopamine. Model simulations
of the effect of progressive cell death on the concentration of
extracellular dopamine. Black: dopamine concentration declines less
than 10 % until more than 80 % of cells have died. White: effect of
reducing the activity of the dopamine reuptake transporter (DAT);
now the level of extracellular dopamine is very sensitive to the size
of the cell population. After [4, 26]
Fig. 1. Topology of the folate and methionine cycles illustrating selected long-range allosteric regulatory interactions. Enzymes are indicated by
ellipses, substrates by rectangles, and the allosteric regulatory actions by red arrows. These allosteric interactions serve to stabilize the DNA methylation
reaction as follows. When S-adenosylmethionine (SAM) rises, due to increased methionine input, for instance, it inhibits 5,10-methylenetetrahydrofolate
reductase (MTHFR). This reduces the level of 5-methyltetrahydrofolate (5mTHF), the co-substrate for methionine synthase (MS). This effect, together with
the inhibition of betaine-homocysteine methyltransferase (BHMT), leads to a reduction in methionine synthesis. SAM also increases the rate of the CBS
reaction, which removes the excess mass from the system. The reduction in 5mTHF, in turn, relieves inhibition of GNMT, causing more flux through this
enzyme, which stabilizes the flux through the DNMT reaction until the level of SAM falls back to normal. Enzymes: AICART aminoimidazolecarboxamide
ribonucleotide transferase, BHMT betaine-homocysteine methyltransferase, CBS cystathionine β-synthase, DHFR dihydrofolate reductase, DNMT DNA-
methyltransferase, FTD 10-formyltetrahydrofolate dehydrogenase, FTS 10-formyltetrahydrofolate synthase, GNMT glycine N-methyltransferase, MAT-I
methionine adenosyl transferase I, MAT-III methionine adenosyl transferase III, MS methionine synthase, MTCH 5,10-methenyltetrahydrofolate cyclohydrolase,
MTD 5,10-methylenetetrahydrofolate dehydrogenase, MTHFR 5,10-methylenetetrahydrofolate reductase, NE non-enzymatic conversion, PGT phosphoribosyl
glycinamidetransformalase, SAAH S-adenosylhomocysteine hydrolase, SHMT serinehydroxymethyltransferase, TS thymidylate synthase. Metabolites: 10f-THF
10-formyltetrahydrofolate, 5mTHF 5-methyltetrahydrofolate, CH= THF 5-10-methenyltetrahydrofolate, CH2-THF 5-10-methylenetetrahydrofolate, DHF
dihydrofolate, Hcy homocysteine, MET methionine, SAH S-adenosylhomocysteine, SAM S-adenosylmethionine, THF tetrahydrofolate
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that uses it [14]. In the folate cycle, for instance, many
enzymes are subject to substrate inhibition [3, 15–17].
As a consequence much of each enzyme is catalytically
inactive under normal folate concentrations. When
folate levels decline, some of the inactive enzyme–folate
complexes dissociate, releasing new active enzyme and
folate. Modeling has shown that in the absence of sub-
strate inhibition flux through the pathway declines linearly
with folate concentration, but in the presence of substrate
inhibition reaction rates stay nearly constant until folate
drops to less than 20 % of its normal level [3]. Folate
substrate inhibition probably evolved as a buffering mech-
anism against seasonal variation in folate availability from
fresh leafy greens in order to maintain critical reactions in
the folate cycle, such as early steps in the synthesis of
purines and pyrimidines for DNA synthesis. Substrate in-
hibition was emphasized by Haldane [18] in 1930, but it
has been treated as a chemical curiosity in much of the lit-
erature even though some 20 % of all known enzymes show
substrate inhibition [19]. In all cases that we have exam-
ined, substrate inhibition serves a biological purpose [14].
Allosteric regulation of enzymes has equally signifi-
cant consequences. As an example, we take the case in
Fig. 1 that shows the methionine and folate cycles with
four allosteric regulations indicated by the red arrows.
S-adenosylmethionine (SAM) is the universal methyldonor in cells, in particular for DNA-methyltransferase
(DNMT), the reaction that methylates DNA. The level
of SAM rises and falls with methionine input. When
SAM starts to fall the inhibition of 5,10-methylenetet-
rahydrofolate reductase (MTHFR) is released, resulting
in more 5-methyltetrahydrofolate (5mTHF), which in
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inhibits the glycine N-methyltransferase (GNMT) reac-
tion. Thus, more methionine is resynthesized and fewer
methyl groups are lost through the GNMT reaction.
The reverse sequence of events happens if SAM starts
to go up. The result is that the level of SAM does not
change very much and the rate of the DNMT reaction
stays fairly constant. This wonderful mechanism was
first elucidated by Wagner and co-workers [20]; we
showed quantitatively how stable the DNMT reaction
rate is to stochastic variation in methionine input [2].
A quite different homeostatic mechanism occurs in
the stabilization of dopamine (DA) in synapses. The con-
centration of DA in the extracellular space is maintained
by a balance between release from the terminal and
reuptake by the DA transporters (DATs), and by autorecep-
tors that sense the DA concentration in the extracellular
space [21, 22]. When the concentration goes down theFig. 3. Effect of short-term variation in amino acid input on metabolite lev
pulses of amino acids are shown by gray bars below the figures, correspon
shown as percentage deviation from the mean. a Two metabolites (SAM a
MTHFR] that show complementary responses. b Reaction velocities of mito
below −100 % are reversals of direction of the reaction). c Dynamic variatio
TS, and AICART and the concentration of glutathione. d Eliminating produc
of the DNMT reaction to variation in input is indicated by the greater ampautoreceptors increase the activity of tyrosine hydroxylase
(TH), the first enzyme in the two-step conversion of tyro-
sine to dopamine [23], and the rate of release of DA from
synaptic vesicles [24–26]. If extracellular DA is too high,
the opposite occurs. We developed a mathematical model
for DA synthesis and release [5, 27, 28], and showed that
the autoreceptor mechanism is very effective at stabilizing
extracellular DA.
Decline of extracellular DA in the striatum, due to the
death of DA neurons in the substantia nigra (SN), is the
immediate cause of Parkinson’s disease (PD). Our math-
ematical model showed that the autoreceptors, together
with the DATs, serve to stabilize extracellular DA in the
face of massive cell death in the SN. Our models showed
that as cells die extracellular DA drops slightly but does
not begin to decline significantly until more than 80 %
of the dopaminergic neurons have been lost (Fig. 2) [5].
This figure is in accord with clinical and postmortemels and reaction velocities in the folate and methionine cycles. Three
ding to three meals over a 24-hour period. Variation in response is
nd 5mTHF) and reaction velocities [cystathionine β-synthase (CBS) and
chondrial and cytosolic serinehydroxymethyltransferase (SHMT; values
n of fluxes throughout the pathway stabilize the velocities of DNMT,
t inhibition by S-adenosylhomocysteine (SAH) increases the sensitivity
litude of the response. After [28, 35]
Table 1 Common large-effect mutations in FOCM and
dopamine metabolism, their effects on the activities of the
respective enzymes, and frequencies in selected populationsa
Gene/enzyme Mutation Activity relative
to wild type
Gene frequenciesb
MS A2756G 50 % 9 % (C), 16 % (US),
20 % (EU)
MS D919G 60 % 17 % (J), 55 % (US)
MTHFR C677T 30 % 51 % (I), 34.5 % (ME),
35 % (US)
MTHFR A1298C 68 % 33 % (I), 33 % (US)
TS 2rpt/3rpt 42 % 48 % (US), 40 % (EU),
8 % (C)
TS 1494del6 24 % 76 % (US), 33 % (C)
CBS M173V 38 % -
CBS A226T 13 % 4.5 % (AA)
CBS R548Q 60 % 0.6 % (S)
CBS T191M 10 % 14–75 % (H)
TH T245P 150 % -
TH T283M 24 % -
TH T463M 116 % -
TH Q381K 15 % Familial
DAT V382A 48 %
DAT hNET 65 %
DAT VNTR10 75 %
aFor references see [34,35]
bUS United States, EU Europe, C China, J Japan, I Italy, S Spain, AA African
Americans, H Hispanics, ME Middle East
CBS cystathionine β-synthase, DAT dopamine reuptake transporter,
MS methionine synthase, MTHFR 5,10-methylenetetrahydrofolate reductase,
TH tyrosine hydroxylase; TS thymidylate synthase
Nijhout et al. BMC Biology  (2015) 13:79 Page 5 of 10findings that show that PD symptoms typically do not
begin to appear until about 80 % of the neurons in the
SN have died.
Dynamic stability against short-term variation
Short-term fluctuations in input are inevitable in meta-
bolic systems because inputs of metabolites can change
dramatically after each meal. The role of the homeostatic
mechanisms in damping the effect of fluctuating inputs
can be illustrated by varying the amino acid input terms
in the model to reflect the changes in their blood values
during and after meals over a 24-hour period [29]. In
Fig. 3 we see the effect of three meals on a few concen-
trations and reaction velocities in an enlarged model of
the folate-mediated one carbon metabolism (FOCM)
system that also includes the mitochondria and the syn-
thesis of glutathione (GSH) [4]. The fluxes in different
parts of the system vary enormously with meals, except
for three critical reactions (e.g., thymidylate synthase,
the rate-limiting step for DNA synthesis, and DNA me-
thyl transferase), and the concentration of GSH (Fig. 3c),
which vary little if at all. This system has the property
that many reactions and substrate levels change dramat-
ically in order to maintain stability of a few critical ones.
This is typical of physiological homeostasis. By removing
the feedbacks one-by-one, or in different combinations,
one can study the degree to which each contributes to
the stabilization of each of the four critical reactions. For
instance, we showed that the inhibition of MTHFR by
SAM has the biggest effect on stabilizing the DNMT reac-
tion, whereas the stimulation of cystathionine β-synthase
(CBS) by SAM has a smaller effect [2]. The well-known
mechanism of product inhibition also has important
stabilization effects. S-adenosylhomocysteine (SAH) in-
hibits all the methyl transferases. Figure 3d shows how
this product inhibition helps stabilize the DNMT reaction.
Stabilization against genetic variation
Our models for FOCM and dopamine and serotonin
[11, 30] metabolism have shown that these homeostatic
mechanisms also stabilize critical phenotypes (the rates
of DNA methylation and the thymidylate synthase reac-
tion, and the concentration of synaptic DA, for instance)
against genetic variation. Given that these metabolic
systems are critical for human health, and that defects
are strongly associated with a variety of disease states
[31–35], we were surprised to find that many of the
genes for enzymes in these metabolic systems have
large-effect high-frequency polymorphisms in human
populations, and the natural question arises as to why
these defective genes persist. Table 1 shows a selection
of polymorphisms, their effects on enzyme activity, and
their frequency in selected populations. It turns out that
although the effects of these mutations are quite large atthe molecular level, the homeostatic mechanisms greatly
reduce their effect at the phenotypic level. This can be
illustrated by a phenotypic landscape graph in which we
plot the phenotype as a function of simultaneous vari-
ation in two of the enzymes (or transporters) in the sys-
tem [36, 37]. Two such landscapes are illustrated in
Fig. 4. As can be seen in Fig. 4a,c, the ‘normal’ genotype,
which we’ll call the wild type, lies in a region where the
landscape is quite ‘flat’ (or, rather, orthogonal to the
phenotypic axis). This means that genetic variation around
the wild type will have little or no effect on the phenotype.
In fact, the polymorphisms from Table 1 are almost all on
the flat regions of the surfaces. This illustrates that big
effects at the enzymatic level (x and y axes) can have little
effect at the phenotypic level (z axis). Thus, these polymor-
phisms constitute what evolutionary biologists call cryptic
genetic variation. Fig. 4b,d show what happens when one of
the regulatory mechanisms (the inhibition of GNMT by
5mTHF) is removed. The landscapes change shape dramat-
ically and are no longer orthogonal to the phenotypic axis.
Thus, an additional mutation that destroys this regulation
Fig. 4. Robustness of phenotypes against genetic variation. These figures are phenotypic landscapes that illustrate the effects of pairwise
combinations of ‘genetic’ variables (x and y axes) on selected phenotypes (z axis). The genetic variables are enzyme activities shown as percentage of
wild type. The large white circles indicate the position of the wild type. The small white circles are the values for various mutations in the underlying
genes (taken from Table 1). a, c Stability of the AICART reaction against genetic variation. The wild type and most mutations lie on a relatively flat
horizontal portion of the phenotypic landscape. Thus, even mutations with large effect at the molecular level can have only a minor effect at the
phenotypic level. b, d The effect of removing the inhibition of GNMT by 5mTHF on the shape of the phenotypic landscape. The grey landscapes are
from the left panels and the colored landscapes show the effect of removing the feedback regulation. After [35]
Nijhout et al. BMC Biology  (2015) 13:79 Page 6 of 10would uncover the accumulated cryptic genetic variation
and cause it to become phenotypic.
Predisposition to disease
The etiologies of some diseases are well understood, but in
many cases the disease is a collection of symptoms that we
have named. Fig. 4c shows aminoimidazolecarboxamide
ribonucleotide transferase (AICART) activity as a function
of methionine synthase (MS) activity and MTHFR activity.
Very low AICART activity would likely be detrimental as
cells would have difficulty dividing because their de novosynthesis of nucleotides would be impaired. The geno-
types with only 30 % activity of MS are very close to the
edge of the cliff over which the AICART activity declines
precipitously. It is tempting to consider such individuals
to be ‘predisposed’ to an AICART-dependent disease be-
cause a change in some variable not pictured (another
mutation or an environmental factor) could push them
over the cliff. Similarly, consider the surface in Fig. 5
where the phenotypic variable is the extracellular DA con-
centration and the genetic variables are the activity of TH
and the DAT. The genotypes with very low TH activity
Fig. 5. Stability of extracellular dopamine against genetic variation.
Homeostasis of dopamine to variation in the activities of TH and DAT.
The wild type is indicated by the large white circle. The positions of
homozygotes and heterozygotes for the seven mutations from Table 1
are indicated by small white circles. The alleles are assumed to act
additively. Most of the mutations lie in the relatively flat region of the
landscape. After [26, 34]
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notypes sometimes show a dystonia [38], involuntary
muscle contractions that affect posture, brought about by
low levels of extracellular DA that can be alleviated by
levodopa. Their placement at the edge of the cliff predis-
poses them to the dystonia, which can be brought on by
changes in the other variables that affect the shape of the
surface.
Personalized medicine
We have shown only a few genotype–phenotype surfaces,
but, of course, we can create such surfaces for all the geno-
typic variables (enzyme and transporter activities) and
phenotypic variables (concentrations, reaction velocities) in
our models and place an individual who has been geno-
typed at a particular spot on each of the surfaces. If the
individual is near the edge of a cliff, medical advice could
suggest lifestyle changes (diet) or drug therapy that would
make the region around the genotypic point flatter and
more homeostatic. We give two examples to explain how
our mechanistic models could be used to do just that.
Suppose that an individual has very low MS activity
and therefore very low AICART activity (Fig. 4c). To
intervene wisely one has to know what the causal con-
nection is between MS and AICART; it’s not obvious
since they are not near each other in the network
(Fig. 1). It’s easy to see in the model (simulations not
shown) that when MS has very low activity then the
concentration of 5mTHF gets very high and the other
folates get very low (a situation know as the folate trap,because all folates are eventually converted to 5mTHF),
so 10-formyltetrahydrofolate (10f-THF) declines and
cannot drive the AICART reaction, which results in a
diminished ability to synthesize nucleotides. Thus, the
goal of the therapy is to reduce the folate trap. This
could be done by giving folate, or it could be done by
giving vitamin B12, which is a co-factor for the MS
reaction. High homocysteine in the plasma is a bio-
marker for the folate trap, so in either case one can test
the efficacy of the strategy by measuring the decrease
in homocysteine.
As a second example, consider the genotypes that are
close to the DA cliff in Fig. 5 because they have low TH
activity and are therefore at risk for dystonia. A good
therapeutic strategy should move them away from the
edge of the cliff, or make the region around the defective
genotype flatter. Our simulations (not shown) indicate
that this can be done by increasing the strength of the
DA autoreceptor effect, either by giving autoreceptor
agonists or by increasing the expression level of the DA
autoreceptors.
Biological variation and virtual population models
What does biological variation mean? It means, for
instance, that no two individuals have exactly the same
folate metabolisms in their liver cells. There are many
reasons for this. Their genotypes are different and that
affects the activity of various folate enzymes. The expres-
sion levels of the genes that code for these enzymes vary
in time depending on what the cell is doing, and are influ-
enced by endocrine factors. Furthermore, during the day,
enormous changes in amino acid inputs occur due to
meals. Finally, many of the enzymes require vitamin co-
factors, and so the reactions depend to some extent on
individual dietary histories over months and years.
To represent individual variation and diversity, we make
population versions of our models. A virtual individual is
created by selecting each parameter from a distribution
centered on its normal value, and then running the pro-
gram to steady-state, and recording the concentrations and
velocities, which represent the phenotypic values for that
individual. If we repeat this process 10,000 times, we get a
database of 10,000 virtual individuals that contains both
genetic variation (in terms of variation in the Vmax and Km
of enzymes), and environmental variation (in terms of vari-
ation in nutrient and micronutrient levels), and the result-
ing phenotypic values [12]. Comparison of the results of
such a virtual population model with extant databases gives
another way of verifying that the deterministic model repre-
sents physiological reality well. Fig. 6, for instance, com-
pares the frequency distributions of tissue folate, plasma
folate, and plasma homocysteine in a virtual popula-
tion model [12] with the corresponding distributions
in two National Health and Nutrition Examination
Fig. 6. (See legend on next page.)
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Fig. 6. A population of virtual individuals. Adding random variation to the parameters of a deterministic model makes it possible to develop
a population of virtual individuals, each with a unique combination of genetic and environmental parameters. Here we illustrate that the
frequency-distribution of tissue folate (a), plasma folate (b), and plasma homocysteine (c) closely matches the corresponding data in two NHANES
databases (modified from [12])
Nijhout et al. BMC Biology  (2015) 13:79 Page 9 of 10Survey (NHANES) studies. As one can see, the fits are
quite good.
Such a virtual population database can now be studied
to discover interesting statistical relationships between
phenotypic, genetic, and environmental variables. The
population model is based on a deterministic model, so
we can use the deterministic model to discover the causal
chain of events that leads to the statistical relationships
seen in the database. In this way, statistical analyses, which
deduce the correlated variation among variables, and
deterministic mathematical models, which can show how
those variable are causally linked, can work together to
elucidate underlying biological function.
Limitations and alternative strategies
All methods and tools have limitations and that is true of
our approach too. Since we stay very close to the under-
lying biology and biochemistry, we can only study meta-
bolic systems where there is a great deal of information
about the component parts and the kinetics of how they
affect each other. Nevertheless, our approach can be used
in other areas besides cell metabolism. There are some
outstanding examples in physiology, such as the regula-
tion of blood pressure [39], and kidney function [40, 41].
Other examples can be found in epidemiology [42, 43],
immunology [44], cancer biology [45, 46], regulation of
the cell cycle [47, 48], insulin and diabetes [49–51] and
various examples worked out in [52].
For biological systems in which little is known about
details or kinetics, phenomenological models that cap-
ture some aspect of the data may be helpful in clarifying
ideas and suggesting targets for experimentation. For
example, this is surely the case in studying the brain,
where the chasm between experimentation at the neural
level and behavior is so vast that models using hypo-
thetical intermediate variables can be valuable. However,
we remark again that experimentation with such models
will tell us things about the underlying biology only if
the parameters have biological meanings and could
potentially be measured by experimentalists.
An approach, favored by some systems biologists, is to
use correlations between phenotypic variables measured
in a population (people or cells) to reverse engineer the
network itself and then to assign strengths to the inter-
actions between the variables by using machine learning
and parameter estimation. We believe such methods are
unlikely to succeed because the underlying biological
processes are highly nonlinear, and nonlinear in manydifferent ways, whereas statistical learning approaches to
parameter estimation depend on linear models or on
models that allow only a restricted type of nonlinearity.
It is unlikely that such approaches could find the roles of
allosteric activation, substrate inhibition, and dynamic sta-
bility to short-term perturbations, robustness to genetic
variation, and gene–environment interactions that we see
in biology, and in our models. Our virtual population
databases could, of course, be used to test whether a re-
construction method can accurately deduce the structure
and kinetics of the network that generated the data.
Statistical approaches on large data sets can be useful
for revealing interesting correlations and relationships
between phenotypic and genetic variables. As we indi-
cated above, we can derive interesting and useful infor-
mation by statistical analyses on our virtual population
databases. And in systems where the biology is largely
unknown, statistical methodology may be the only useful
set of tools that one has. However, one must always
remember that correlation is not causality. Until one un-
derstands mechanism, designing experiments or interven-
tion strategies (whether via drugs, life style changes, or
surgery) based on the model is difficult and risky.Conclusions
The main point of this article is to explain that mathe-
matical models are a useful tool for investigating a large
number of questions in metabolism, genetics, and gene–
environment interactions. If the model is based on the
underlying biology and biochemistry, then it becomes a
platform for in silico biological experimentation and it can
also reveal the causal chain of events that connect vari-
ation in one quantity to variation in another. The variables
and parameters in the model must be related, directly or
indirectly, to quantities that biologists measure, so that ex-
periments with the model have biological meaning. The
metabolic systems that have evolved are very complicated,
subtle, and difficult to understand. There is no substitute
for detailed biological experimentation on the biology and
the biochemistry of the parts. But mathematical models,
based on the real biology, can shed light on how the parts
work together and the causal relationships between them,
and suggest strategies for interventions in disease states.
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